MST estimates assume that positive results in trofinetide’s Phase 3 trials and NNZ-2591’s Phase 2 trial will trigger milestone payments over CY21-CY23 of ~A$146m, almost equal to its current market cap.
Honestly, I can’t follow this analyst.
Firstly, my understanding was that there will be 3 Phase 2 trials of NNZ-2591 run simultaneously, so why use of the singular “trial”?
Secondly, why would the analyst consider that success in Phase 2 with NNZ-2591 will trigger milestone payments when Neuren hasn’t signed any deal for NNZ-2591?
Updated MST report - target of $3.68 a share, page-3
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.25 |
Change
0.430(2.17%) |
Mkt cap ! $2.585B | |||
| Open | High | Low | Value | Volume |
| $19.89 | $20.39 | $19.77 | $5.715M | 283.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 355 | $20.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.29 | 302 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.22 |
Change
0.430 ( 2.40 %) |
||||
| Open | High | Low | Volume | ||
| $19.86 | $20.40 | $19.77 | 85257 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| NEU (ASX) Chart |